PPARG and fatty liver disease: Currently, vitamin E is recommended to treat NASH patients, associated with reduced serum hepatobiliary enzymes and hepatic steatosis but without improvement of liver fibrosis.62,282,283 In a large-sample, randomized, double-blind, controlled, phase 3 clinical trial (NCT00063622), the efficacy of vitamin E with another antidiabetic agent (Pioglitazone, targeting PPARγ) was confirmed in non-diabetic patients with NASH with histological evaluation as the study endpoint.